Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | CD69 | Q07108 | 1/20 | 0.36 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.33 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.33 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.33 |
| ▸ | MAG | P20916 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | MMP12 | P39900 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25964076 | 0.82 | MAPK1 (0.41) | MAPK1ALDH1A1THRBCD69NOD2 | |
| SCHEMBL14089003 | 0.82 | ALDH1A1 (0.48) | MAPK1ALDH1A1THRBCD69NOD2 | |
| SCHEMBL25963112 | 0.81 | MAPK1 (0.47) | MAPK1ALDH1A1THRBCD69NOD2 | |
| SCHEMBL13994673 | 0.77 | MAPK1 (0.41) | MAPK1ALDH1A1THRBCD69LGALS3 | |
| SCHEMBL21743003 | 0.74 | MAPK1 (0.39) | MAPK1ALDH1A1THRBCD69NOD2 | |
| SCHEMBL20841310 | 0.72 | MAPK1 (0.48) | MAPK1ALDH1A1THRBCD69NOD2 | |
| SCHEMBL21146727 | 0.72 | LGALS3 (0.56) | MAPK1ALDH1A1THRBCD69LGALS3 | |
| SCHEMBL791244 | 0.72 | MAPK1 (0.79) | MAPK1ALDH1A1THRBCD69NOD2 | |
| SCHEMBL13994672 | 0.71 | MAPK1 (0.40) | MAPK1ALDH1A1THRBCD69NOD2 | |
| SCHEMBL13246090 | 0.71 | MAPK1 (0.47) | MAPK1ALDH1A1THRBCD69NOD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230256109-A1 | Trans-Cyclooctene Bioorthogonal Agents and Uses in Cancer and Immunotherapy | TAMBO, INC. | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230256109-A1 | Trans-Cyclooctene Bioorthogonal Agents and Uses in Cancer and Immunotherapy | ICOS, CD74, PBK | MAPK1 3636/4885ALDH1A1 3456/4885THRB 1497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.